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MATERIALS AND METHODS
Cell
tal neuroblastoma cell lines and subclones with a neuronal (N) differentiation phenotype, whereas lower levels of c-kit mRNA were associated with neuroblastoma cell line subclones having a schwannian/glial/melanocytic pattern of dfferentiation. However, the differentiation phenotype of neuroblastoma cell lines was not directly attered when c-kit expression was blocked using the SR-1 antibody. In summary, these data indicate that c-kit receptor expression may play a significant role in the growth regulation of the two neuroblastoma cell lines examined and suggest that c-kit may also play a similar role in neuroblastoma growth regulation in vivo. Simultaneous expression of SCF and c-kitmRNA in both neuroblastoma cell lines and tumors implies that ckit may act as part of an autocrine growth loop in conjunction with endogenous production of SCF in this disease.
6 7994 by The American Society of #emato/ogy. mercaptoethanol (&ME), and 5 ng/mL purified human granulocytemacrophage colony-stimulating factor (GM-CSF; Sigma, St Louis, MO). W-I cells assayed for SCF-induced cell proliferation were washed free of serum and growth factors and placed in a serum-free media containing Iscove's modification of DMEM, plus 1.6% bovine serum albumin (BSA), 0.2 mg/mL iron-saturated human transfenin (ICN, Wine, CA), 5x10' m o m @-ME, 0.67% human low-density lipoprotein (Sigma, St Louis, MO), and varying concentrations of SCF or control diluent. All cells were refed every 2 to 3 days for time points up to IO days. One microcurie of 3H-thymidine was added to each well and cells were incubated for an additional 6 hours before harvesting and scintillation counting.
To test the growth inhibitory response of neuroblastoma cells to anti-c-kit antibody, either no antibody, irrelevant isotype-controlled antibody (IgG2-antihuman A Ig chain; Pharmingen, San Diego, CA), or the mouse monoclonal antihuman c-kit blocking antibody SR-I" (supplied by Amgen, Inc) were added to neuroblastoma cells growing in complete medium at a final concentration of l pg/mL. Cultures were refed every 3 to 4 days for up to 10 days of culture and assayed for 3H-thymidine incorporation as described above.
Preparation of total RNA and Northern blot analysis. Total cellular RNA was isolated from cell lines grown in monolayer by the Chomczynski and Sacchi method." Total RNA from 18 neuroblastoma tumors obtained from patients registered with the Chil- dren's Cancer Group was prepared by the same method. Northern blots were prepared as described previously." The DNA fragment or plasmid probes used in this study included human probes for the following genes: ne~rofilament,'~ L-NGFR," tyrosinase,I6 and Pactin." Reverse transcriptase-polymerase chain reaction (RT-PCR). Total RNA preparations from various cell lines were subjected to RT-PCR. Primers used for analyses of SCF, c-kit, and P2-microglobulin (P2-m) mRNA expression were based on published sequence information for each genels-*" and were selected to skip at least one intron to specifically detect mRNA. The sequences used are shown in Table  I . RT-PCR using the c-kit primers described resulted in two bands representing known alternatively spliced transcripts that differ by 12 bp in size." Reverse transcription of 0.5 pg of total RNA was performed for 30 minutes at 42'C using 2.5 U/pL Moloney murine leukema virus (M-MLV) RT in 1 X RT-PCR buffer (IO mmoVL Tris-HCI, pH 8.3, 50 mmol/L KCI, 5 mmoVL MgCI?, and 1 mmoV L each of dATP, dGTP, dCTP, and dTTP) containing 1 U/pL RNasin (Promega, Madison, WI) and 0.15 pmol/L of random primers. Samples for PCR contained 10 pL cDNA; 1.25 U AmpliTaq DNA polymerase; 10 mmoVL Tris-HCI, pH 8.3; 50 mmoUL KCI; 2 mmol/L MgCI2; 1 U/pL RNasin (Promega); 1 mmoVL each of dATP, dGTP, dCTP, and dTTP; and 0.15 pmol/L upstream and downstream primers for the gene of interest. The reaction mixture final volume was 50 pL and was overlaid with 25 pL mineral oil. Samples were amplified for 1 cycle at 94OC for 5 minutes and 6OoC for 2 minutes and then amplified for 38 sequential cycles at 94OC for I minute and 6OoC for 2 minutes. The final extension cycle was 94OC for 1 minute and 60°C for 10 minutes. One-tenth (5 pL) of each completed RT-PCR reaction was then electrophoresed on a 1% agarose/2% NuSieve GTG gel and stained with ethidium bromide.
To enhance detection of SCF or c-kit mRNA expression by RT-PCR, the electrophoresed RT-PCR products obtained using SCF-or c-kit-specific primers were then subjected to Southern blotting and hybridization using a 32P-labeled SCF or c-kit probe. Ethidium gels containing the RT-PCR products were transferred to Nytran membranes (Schleicher and Schuell, Keene, NH) and then placed in a hybridization solution containing 0.5 m o m NaPO,, 1 m m o K EDTA, 1% BSA, 7% sodium dodecyl sulfate (SDS), 100 pg/mL salmon sperm DNA, and IO7 cpm/mL of 32P-labeled probe. These blots were hybridized for 16 hours at 65°C and washed twice with 2 x SSC, 0.1% SDS, and twice with 0.1X SSC, 1% SDS for 15 minutes at 65 'C. Autoradiography was performed on Kodak X-Omat AR film (Eastman Kodak, Rochester, NY). Probes were prepared by performing RT-PCR using the SCF or c-kit primers described above on mRNA from a cell line known to express SCF or c-kit [HepG2 or HL60(k), respectively] and electrophoresis of RT-PCR products on a 1% agarose gel and by cutting out the desired DNA fragment from the gel and labeling it with random "P-dCTP-labeled oligonucleotide primers.'* Clonogenic assay. A total of 5 X IO3 cells/well were plated in triplicate in RPM1 1640 plus penicillin, streptomycin, and L-glutamine with 10% heat-inactivated FCS, 0.3% agar, and 1 pg/mL of SR-1 or MOPC 21 irrelevant, nonisotype controlled antibody (Cappel, Inc. Durham, NC) in 12-well plates for 14 days. After this time period, cultures were stained using 24 hours of incubation with a sterile 0.5 mg/mL solution in water of
2-(p-iodophenyl)-3-(p-ni-
trophenyl)-5-phenyl tetrazolium ~hloride.'~ Cultures were photographed and total colony number was calculated. Using a simultaneously photographed micrometer, colonies were tabulated and counted according to size.
RESULTS
Detection of SCF a n d c-kit mRNA in neuroblastoma cells. To initially determine whether SCF and c-kit play a role in neuroblastoma, SCF and c-kit mRNA expression in neuroblastoma cell lines was analyzed using the technique of RT-PCR. Figure Thus, all neuroblastoma cell lines and clones and the one neuroepithelioma cell line examined appear to coexpress mRNA for SCF and c-kit. RT-PCR of mRNA from these cell lines for P2-m mRNA expression was also performed to control for mRNA integrity (Fig 1C) .
In Fig 1B and D, Fig 1B and D. c-kit mRNA is easily detectable and is thus expressed at higher levels in the parent cell lines SK-N-BE(2), SK-N-SH, and LA-N-1, as well as in the Nclones BE(2)-M17, and SH-SYSY. c-kit mRNA levels are lower in the I-clone BE (2) LA-N-1-5s. Thus, parental cell lines and their N-clones express markedly greater amounts of c-kit mRNA than their respective I-or S-clones.
Neuroblastoma tumors were then examined for c-kit and SCF mRNA expression by RT-PCR to see whether the coexpression of c-kit and SCF mRNA found in neuroblastoma cell lines was also a feature of neuroblastoma tumors. Total RNA from 18 neuroblastoma tumors was subjected to RT-PCR analysis of SCF and c-kif mRNA expression. In addition, RT-PCR analysis of P2-m was performed on each sample to show the integrity of tumor mRNA samples in which c-kif and SCF expression could not be detected. Eight of I8 (45%) of tumor samples analyzed express both SCF and ckif mRNA, and none of these tumors express SCF or c-kit alone (Fig 2) . The double band seen in Fig 2B represents alternative c-kit mRNA transcripts that vary by 12 bp because of an alternative splice site between exons 9 and IO. The multiple bands seen in lane 7 of Fig 2A appeared on multiple RT-PCR attempts and are unexplained, but may represent mutation of the SCF gene in this tumor sample or RT-PCR artifact. The lack of SCF and c-kif mRNA expression by ethidium staining in negative samples was confirmed by hybridization of these gels with radiolabeled SCF or ckif probes (data not shown). Thus, SCF and c-kif are simultaneously expressed in a large subset of neuroblastoma tumors, similar to our findings in the cell lines. The tumors that were analyzed represent a spectrum of Evans' stage, age at diagnosis, and MYCN DNA amplification, all data obtained previously (Table 3) . However, no statistical significance can be derived regarding the relationship between SCFlc-kif expression and other neuroblastoma prognostic factors, given the small sample size.
Effect of anti-c-kit antibody on neuroblastoma cell growth. Because simultaneous expression of SCF and ckit mRNA was a consistent finding in neuroblastoma cell lines and a frequent finding in neuroblastoma tumors, these data suggested the existence of an autocrine loop involving SCF and c-kit in neuroblastoma. To test whether c-kif expression contributes to neuroblastoma cell growth, the neuroblastoma cell line SK-N-BE(2) and its I-clone BE(2)-C were initially treated in culture with varying concentrations of SCF for up to IO days and assayed for changes in growth using a "-thymidine uptake assay. As a positive control, the human erythroleukemia cell line TF-1, which expresses For personal use only. on October 26, 2017. by guest www.bloodjournal.org From a functional c-kit receptor but not its ligand SCF, was also tested for proliferative response to SCF in a similar manner. No significant proliferative response to SCF was detected with either neuroblastoma cell line tested, whereas the TF-I cell line proliferated in an expected dose-dependent manner in response to SCF, as has been described"' (data not shown).
Because both neuroblastoma cell lines coexpress SCF and c-kit mRNA. a proliferative response to exogenous SCF may not have been observed because of already maximal stimulation of an autocrine loop, which could not be further stimulated by additional, exogenous SCF. To test this possibility, we used a blocking monoclonal antibody to the human c-kit receptor. SR-I , to determine whether an exogenous blockade of c-kit receptors in the face of endogenous SCF expression might affect neuroblastoma cell growth. Two cell lines, SK-N-BE(2) and SH-SYSY, were chosen for this experiment because they make relatively larger amounts of c-kit transcripts, as shown by RT-PCR (Fig I) .
Alterations in the growth of the SK-N-BE(2) and SH-SYSY cell lines after treatment with SR-I antibody were first measured by the 'H-thymidine uptake assay. A significant decrease is observed in ?H-thymidine incorporation in both SH-SYSY and SK-N-BE(2) cells treated with anti-c-kit antibody when compared with controls (Fig 3) . In SH-SYSY cells, there is approximately a SO% decrease in 'H-thymidine uptake by day 6, which persists through day 8. SK-N-BE (2) cells show a more marked growth inhibition, reaching 75% by day 7. This effect was entirely reversible with removal of antibody in both cell lines (data not shown).
The addition of anti-c-kir antibody also has a significant effect on the clonogenicity of neuroblastoma cell lines grown in soft agar (Fig 4) . Both the total number (Fig 4A) and the size of neuroblastoma colonies (Fig 4B) decreases when grown in agar-containing SR-I antibody for 14 days when compared with the number of colonies resulting from culture with either no additional antibody (control) or with irrelevant MOPC 21 antibody. For the cell line SK-N-BE(2), there is a 25% decrease in total colony count and a significant 64% decrease in the growth of colonies greater than 100 p m in diameter when treated with SR-I antibody compared with control treated cells. In these experiments, SK-N-BE(2) cells treated with MOPC 21 also showed a 21% decrease in growth of colonies greater than 100 pm compared with control, but this decrease is significantly less than that seen after SR-I treatment. In the SH-SYSY line, there is a 39% decrease in total colony count and a 60% decrease in growth of colonies of greater than 1 0 0 pm in diameter when treated with SR-I antibody compared with control or MOPC 21 antibody-treated cells.
Lack qf direct effect oj-anti-c-kit antibody on neuroblastoma differenriation. Because there was a difference in the level of c-kit mRNA expression that correlated with the differentiation phenotype of neuroblastoma subclones 7 8 9 10 11 12 13 14 15 16 17 18 its receptor c-kit was detected in 14 of 14 human neuroblastoma cell lines and clones (Fig 1 ) and in 8 of 18 lwman neuroblastoma tumor samples (Fig 2) . Blockade of c-kit function in the cell lines SK-N-BE(2) and SH-SYSY using the SR-1 antibody results in a significant decrease in neuroblastoma growth rate when measured by either the 3H-thymidine uptake assay (Fig 3) or clonogenic assay (Fig 4) . Thus, these data indicate that growth is significantly regulated by c-kit receptor expression in the two neuroblastoma cell lines examined, possibly as part of an autocrine growth loop in conjunction with autocrine secretion of SCF.
The concept that SCF may play a trophic role in cells derived from neural crest has been substantiated by recent studies in human and animal systems. Table 1) . However, blockade of c-kit receptor expression of N-type subcloned neuroblastoma lines does not change the differentiation phenotype of cells that are known to be characteristic of S-subclones. In particular, no decrease is observed in neurofilament and L-NGFR mRNA, concomitant with an increase in tyrosinase mRNA expression, which is the pattern to be expected if cells switched from N-to S-type after SR-I treatment. Thus, although higher C-kit &A expression may be consistent with a neuronal, or N-type pattern of differentiation, c-kit does not appear to directly regulate neuroblastoma differentiation along the neuronal pathway. Instead, higher c-kit expression may be an epiphenomenon of the neuronal differentiation program of neuroblasts, as is the case with other genes such as bc12, which is expressed in N but not S neuroblastoma clones.34
Coexpression of SCF and c-kit mRNA has been reported in other human malignancies, including some acute myeloid leukemias, small cell lung carcinoma, and breast carciThese findings suggest the possibility that an autocrine growth loop involving the SCFlc-kit system exists in some tumors. However, to date, investigators have been unable to successfully show a functional autocrine loop in any cell lines that coexpress SCF and c-kit when blocking antibodies to c-kit were used in assays of soft agar colony formation or tritiated thymidine
The data presented here are the first to show changes in growth rate and clonogenicity as a result of c-kit receptor blockade in a tumor that coexpresses SCF and c-kit mRNA, strongly implicating an autocrine growth regulatory role of SCF and c-kit in neuroblastoma.
One feature of SCF function, regardless of the target organ, is that it stimulates growth best in synergy with other growth factors. In the hematopoietic system, SCF itself has little capacity to stimulate colony formation in progenitor assays in vitro, but it acts as a potent growth factor when added in combination with other hematopoietic growth factors such as erythropoietin, interleukin-3 (1L-3), XL-6, XL-7, and GM-CSF.'8, 35 In murine primordial germ cells in vitro:' SCF administered in combination with leukemia inhibitory factor and bFGF enhances cell proliferation and survival of primordial germ cells. In melanocytes, SCF has no activity on its own, but is a mitogen in the presence of 12-o-tetradecanoylphorbol-13-acetate (TPA), which may mimic the action of some as yet uncharacterized melanocytic growth factor." Given this paradigm of synergistic growth in other target tissues, it will be of interest to see whether other known neuroblastoma growth factors, such as IGF-11, FGF, NGF, and BNDF, may synergize with SCF to enhance neuroblastoma g r o w t l~?~.~~ Whether c-kit and SCF plays a significant role in the growth of neuroblastoma tumor cells in vivo remains to be determined. It is possible that the SCF and c-kit mRNA transcripts detected in mRNA extracted from tumor samples derive not from the tumor cells themselves, but from contaminating hematopoietic cells within the sample. However, the other evidence presented here strongly argues for a functional role of SCF and c-kif coexpression in the cell lines examined, making it likely that SCF and c-kit coexpression play a similar role in at least a subset of neuroblastoma tumors in vivo. These data also suggest that the c-kit receptor may be a target for therapeutic intervention in neuroblastoma patients.
In patients receiving autologous bone marrow transplantation for neuroblastoma, hematopoietic growth factors may be used either to harvest peripheral stem cells or to speed recovery during the period of posttransplant bone marrow aplasia. Because c-kit is involved in neuroblastoma growth regulation, these findings raise concern regarding the potential proliferative effect of exogenous SCF on residual neuroblastoma cells left in harvested marrow or other sites. However, it is possible that c-kir receptors are maximally stimulated by endogenously produced SCF, SO that additional exogenous SCF may not further enhance neuroblastoma growth, similar to what is seen in vitro. Thus, it remains to be seen whether treatment of patients with SCF, in the context of bone marrow transplant for example, will adversely affect outcome, but use of SCF in patients with neuroblastoma should be approached with caution.
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